Phase 2 study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 (CCL2), in metastatic castration-resistant prostate cancer

Investigational New Drugs

Volumn 31, Issue 3, 2013, Pages 760-768

  Pienta, Kenneth J ^a   Machiels, Jean Pascal ^b   Schrijvers, Dirk ^c   Alekseev, Boris ^d   Shkolnik, Mikhail ^e   Crabb, Simon J ^f   Li, Susan ^g   Seetharam, Shobha ^g   Puchalski, Thomas A ^g   Takimoto, Chris ^g   Elsayed, Yusri ^h   Dawkins, Fitzroy ^h   De Bono, Johann S ⁱ  

^a UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

^b CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^c ZiekenhuisNetwerk Antwerpen   (Belgium)

^d P A Herzen Research Oncological Institute   (Russian Federation)

^e Russian Center for Research in Radiological and Surgical Technologies   (Russian Federation)

^f UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^g JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^h JANSSEN RESEARCH AND DEVELOPMENT   (United States)

ⁱ INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

Carlumab; CC chemokine ligand 2; CC chemokine receptor 2; Prostatic neoplasms

Indexed keywords

CARLUMAB; DRUG ANTIBODY; MONOCYTE CHEMOTACTIC PROTEIN 1; PROSTATE SPECIFIC ANTIGEN;

AGED; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTHRALGIA; ARTICLE; BACKACHE; BONE METASTASIS; BONE PAIN; CASTRATION RESISTANT PROSTATE CANCER; CLINICAL ARTICLE; CONFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DECREASED APPETITE; DIGESTIVE SYSTEM PERFORATION; DRUG BLOOD LEVEL; DRUG INFUSION; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; HUMAN; IMMUNOGENICITY; INFUSION RELATED REACTION; MALE; METASTASIS; MULTICENTER STUDY; MULTIPLE ORGAN FAILURE; MUSCULOSKELETAL PAIN; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SCORING SYSTEM; SPINAL CORD COMPRESSION; STEADY STATE; THROMBOCYTOPENIA;

AGED; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; ANTINEOPLASTIC AGENTS; CELL COUNT; CHEMOKINE CCL2; ENDOTHELIAL CELLS; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASTIC CELLS, CIRCULATING; ORCHIECTOMY; PROSTATIC NEOPLASMS;

EID: 84879085632     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-012-9869-8     Document Type: Article

References (26)

1. Siegel R, Naishadham D, Jemal A (2012) Cancer statistics, 2012. CA Cancer J Clin 62:10-29
2. Walczak JR, Carducci MA (2007) Prostate cancer: a practical approach to current management of recurrent disease. Mayo Clin Proc 82:243-249
3. Lu Y, Cai Z, Xiao G, et al. (2007) CCR2 expression correlates with prostate cancer progression. J Cell Biochem 101:676-685
4. Garmey EG, Sartor O, Halabi S, Vogelzang NJ (2008) Second-line chemotherapy for advanced hormone-refractory prostate cancer. Clin Adv Hematol Oncol 6:118-132
5. Tannock IF, de Wit R, Berry WR, et al. (2004) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351:1502-1512
6. Berthold DR, Pond GR, Soban F, de Wit R, Eisenberger M, Tannock IF (2008) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol 26:242-245
7. de Bono JS, Logothetis CJ, Molina A, et al. (2011) Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 364:1995-2005
8. de Bono JS, Oudard S, Ozguroglu M, et al. (2010) Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 376:1147-1154
9. Lu Y, Cai Z, Galson DL, et al. (2006) Monocyte chemotactic protein-1 (MCP-1) acts as a paracrine and autocrine factor for prostate cancer growth and invasion. Prostate 66:1311-1318
10. Mazzucchelli L, Loetscher P, Kappeler A, et al. (1996) Monocyte chemoattractant protein-1 gene expression in prostatic hyperplasia and prostate adenocarcinoma. Am J Pathol 149:501-509
11. Lu Y, Xiao G, Galson DL, et al. (2007) PTHrP-induced MCP-1 production by human bone marrow endothelial cells and osteoblasts promotes osteoclast differentiation and prostate cancer cell proliferation and invasion in vitro. Int J Cancer 121:724-733
12. Loberg RD, Day LL, Harwood J, et al. (2006) CCL2 is a potent regulator of prostate cancer cell migration and proliferation. Neoplasia 8:578-586
13. Li X, Loberg R, Liao J, et al. (2009) A destructive cascade mediated by CCL2 facilitates prostate cancer growth in bone. Cancer Res 69:1685-1692
14. Loberg RD, Ying C, Craig M, Yan L, Snyder LA, Pienta KJ (2007) CCL2 as an important mediator of prostate cancer growth in vivo through the regulation of macrophage infiltration. Neoplasia 9:556-562
15. Loberg RD, Ying C, Craig M, et al. (2007) Targeting CCL2 with systemic delivery of neutralizing antibodies induces prostate cancer tumor regression in vivo. Cancer Res 67:9417-9424
16. Sandhu SK, Fong PC, Frentzas S, et al. (2009) First-in-human, first-in-class, phase I study of a human monoclonal antibody CNTO 888 to the CC-chemokine ligand 2 (CCL2/MCP-1) in patients with solid tumors. J Clin Oncol 27:e13500
17. Eisenhauer EA, Therasse P, Bogaerts J, et al. (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228-247
18. Scher HI, Halabi S, Tannock I, et al. (2008) Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 26:1148-1159
19. Cancer Pain Relief with a Guide to Opioid Availability. (1996) World Health Organization, Geneva, Switzerland
20. Cleeland CS (2006) The measurement of pain from metastatic bone disease: capturing the patient's experience. Clin Cancer Res 12:6236s-6242s
21. Halabi S, Vogelzang NJ, Kornblith AB, et al. (2008) Pain predicts overall survival in men with metastatic castration-refractory prostate cancer. J Clin Oncol 26:2544-2549
22. Danila DC, Heller G, Gignac GA, et al. (2007) Circulating tumor cell number and prognosis in progressive castration-resistant prostate cancer. Clin Cancer Res 13:7053-7058
23. de Bono JS, Scher HI, Montgomery RB, et al. (2008) Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res 14:6302-6309
24. Haringman JJ, Gerlag DM, Smeets TJ, et al. (2006) A randomized controlled trial with an anti-CCL2 (anti-monocyte chemotactic protein 1) monoclonal antibody in patients with rheumatoid arthritis. Arthritis Rheum 54:2387-2392
25. Puchalski T, Han C, McIntosh T, et al. (2012) A novel preclinical study in cynomolgus monkeys examining CCL2 production rate and kinetic profile after escalating dose administration of anti-CCL2 human monoclonal antibody carlumab (CNTO 888). AACR Abstract #2518
26. Fetterly GJ, Puchalski T, Takimoto C, et al. (2010) Utilizing mechanistic PK/PD modeling to simultaneously examine free CCL2, total CCL2, and CNTO 888 serum concentration time data. J Clin Oncol 28:3029, Abstract